- 01-05-2010, 03:58 PM
have been hearing alot of people talking with PH's starting to go away that the new body building supplement will be peptides. Trying to research them and info is very vague even with google and the info technology. I have found them on the internet but trying to undrstand what they do, how they work. It seems they are an injectable. Anyone have experience with them? Dosages? How often? Thanks for any help.
- 01-05-2010, 04:14 PM
the peptides forum will better suit ur needs.
most common are:
and there are many many others
- 01-05-2010, 05:00 PM
Drug Classification: Growth-Hormone- Releasing Peptide
Active LIfe: 5-8 days
It is important to begin the discussion of CJC-1295 with a discussion of the parent of the Growth Hormone Releasing Factors which is somatocrinin., this peptide ultimately gave birth to the newer generations of Growth-hormone-releasing hormone peptides (CJC-1295).
Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF or GHRF) or somatocrinin, is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus. GHRH is released from neurosecretory nerve terminals of these arcuate neurons, and is carried by the hypothalamo-hypophysial portal circulation to the anterior pituitary gland where it stimulates growth hormone secretion. GHRH stimulates the production of growth hormone.
GHRH gave birth to a more compact growth hormone releasing factor known as Sermorelin which is a synthetic analogue of growth hormone releasing hormone, which is produced by the hypothalamus. Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.
The free base of sermorelin has the empirical formula C 149 H 246 N 44 O 42 S and a molecular weight of 3,358 daltons. Sermorelin stimulates the secretion of growth hormone by acting directly on the pituitary gland, in the brain. In contrast to GHRH which is a 44 amino acid sequence Sermorelin is a 29 amino acid peptide hormone and is also known as (GRF 1-29 NH2). Sermorelin was sold in the United States with the brand name GEREF by Serono Biotechnologies, which later was sold to Merck, they stopped production of Sermorelin in November 2002.
So, what was the problem with Sermorelin, or GHRH for that matter? The clinical use of growth hormone-releasing hormone (GHRH) is limited by its short half-life. Also it follows that Sermorelin faced the same difficulties and thus is limited by its short half life (approximately 12 min following intravenous injection in humans), mainly due to its susceptibility to rapid enzymatic degradation. Thus, the product quickly dissipated in the body and the peptide could not stay in the body long enough to have a medicinal impact. A Munafo, T X Q Nguyen, O Papasouliotis, H Lécuelle, A Priestley and M O Thorner (2005). There were attempts to resolve some of the short half-life issues with Sermorelin, in fact a PEGylated GHRH was developed. Even though PEGylated GHRH solved some of the degradation issues, the much more potent CJC 1295, rendered PEGylated GHRH obsolete.
Instead of using a PEGylated technology, the technology of bioconjugation was employed. In vivo bioconjugation to serum albumin is a useful tool to increase the half-life of small molecules or peptides in plasma. In vivo bioconjugation occurs when a strategically placed reactive group on a bioactive peptide reacts with a nucleophilic entity found in blood or in sc interstitium to form a stable bond. The foremost nucleophile is the thiol, and its most abundant source in these fluids is Cys34 on albumin. The thiol on Cys34 reacts with a Michael acceptor, such as a maleimido derivative, leading to a new bioactive protein construct that will adopt an extended half-life due to stabilization from enzymatic degradation) or reduced elimination through the kidney. It therefore became logical to combine the long-lasting effect of bioconjugation with the proper GRF analog. Lucie Jetté, Roger Léger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, Véronique Paradis, Pieter van Wyk, Khan Pham and Dominique P. Bridon (2005).
CJC-1295 is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation. By applying the Drug Affinity Complex (DAC) technology to GRF, the peptide selectively and covalently binds to circulating albumin after subcutaneous (SC) administration, thus prolonging its half-life. These substitutions are key in increasing the overall half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days. Bioconjugation takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucelophile by this particular peptide thanks to a Cys34 thiol group that attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity for albumin.
So how effective is bioconjugation? How long will CJC-1295 stay in ones system? How will CJC-1295 impact IGF-1 levels? This is the exact question researchers asked and a study was conducted to determine the efficacy of CJC-1295. The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 days. Healthy subjects, ages 21-61 years old were studied. After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days. The estimated half-life of CJC-1295 was 5.8-8.1 days. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 days. No serious adverse reactions were reported. Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne and Lawrence A. Frohman (2006). What was the research dose used in the study? A particularly important question, the dosage was 30-60 micrograms per kilogram of bodyweight.
So in sum, what is CJC-1295? CJC-1295 is a long-acting analog of GH-releasing hormone. CJC-1295 exhibits the same effects of Human Growth Hormone, it has the ability to promote muscle mass, increase bone density, improve protein synthesis, increase IGF-1 levels potently, strengthen immune systems, stimulate the production of bone marrow cells that produce red blood cells, and of course reduce excess body fat, especially abdominal fat. (The reduction of abdominal fat is the single most profound effect of HGH replacement.)
Reply With Quote
09-12-2011, 07:24 PM
hi!! some body know where i can have peptides on line ( ghrp-6 , ipamorelin , melanotan 2 , igf-1 ..... ) in canada ???
Similar Forum Threads
- By russiandave in forum IGF-1/GHReplies: 8Last Post: 09-01-2010, 05:07 PM
- By jtnba24 in forum IGF-1/GHReplies: 8Last Post: 02-04-2009, 02:36 PM
- By just93 in forum IGF-1/GHReplies: 10Last Post: 10-30-2008, 10:07 PM
- By dangerbird in forum IGF-1/GHReplies: 12Last Post: 12-09-2007, 09:08 PM
- By szeleale in forum IGF-1/GHReplies: 1Last Post: 11-14-2007, 08:26 PM